Demis Hassabis

Guest · 2 tracked predictions · 100.0% accuracy

Resolved only

1 resolved · 2 total

Right	1 (50.0%)
Wrong	0

Small sample size (2 predictions): treat this accuracy figure as anecdotal, not statistically meaningful.

Predictions

Google DeepMind CEO Demis Hassabis on AI, Creativity, and a Golden Age of Science | All-In Summit Too Early Fri, 12 Sep 2025 21:33:00 +0000 · 00:19:21

Artificial general intelligence (AGI) capable of true creative/intuitive leaps and consistent PhD-level performance across the board will arrive within 5 to 10 years of this interview (by approximately 2030-2035).

“I think that we are maybe you know I would say sort of five to 10 years away from having an AGI system that's capable of doing those things.” View on YouTube

Explanation

This is a 5-10 year forecast (to roughly 2030-2035) made in September 2025. As of August 2026, no system has been widely recognized as meeting Hassabis's own bar for AGI (true creative/intuitive leaps, consistent PhD-level generality). The timeframe has not elapsed, so this cannot be evaluated yet.

Google DeepMind CEO Demis Hassabis on AI, Creativity, and a Golden Age of Science | All-In Summit Right Fri, 12 Sep 2025 21:33:00 +0000 · 00:25:25

Isomorphic Labs will enter the pre-clinical phase (handing drug candidates to pharma partners) sometime in 2026.

“we'll be entering sort of pre-clinical phase sometime next year. So candidates get handed over to the pharma company and they then take them forward.” View on YouTube

Explanation

Isomorphic Labs' collaborations with Eli Lilly and Novartis progressed from target identification to generating multiple AI-designed preclinical candidates by early 2026, matching Hassabis's 'sometime next year' prediction, and the company is now targeting a first-in-human trial for an IsoDDE-designed candidate by end of 2026.